Magnesium sulphate in patients with thrombotic thrombocytopenic purpura (MAGMAT): a randomised, double-blind, superiority trial
Authors' conclusion
Among patients with TTP, the addition of magnesium sulphate to the standard of care did not result in a significant improvement in time to platelet normalisation.
Study context
- Population
- Adults with a clinical diagnosis of thrombotic thrombocytopenic purpura (TTP)73 analysed
- Participants
- 74 adults
- Comparison
- Magnesium sulphate vs placebo, added to standard treatment
- Magnesium sulphaten = 35
- Placebon = 38reference
- Primary endpoint
- Median time to platelet normalisation (platelet count ≥ 150 G/L)
Methodological detailsmulticentre, double-blind, superiority
- Multicentre
- Double-blind
- Superiority
Primary result
As reported in the abstract
Time to platelet normalisation (platelet count ≥ 150 G/L)
- Cause-specific HR of response
- 0.93 (95% CI 0.58-1.48, p = 0.75)
Further findings
Events
| Outcome | Magnesium sulphate | Placebo | P value |
|---|---|---|---|
| Death · day 90 | 4 | 2 | P = 0.42 |
Safety
Low BP (most frequent adverse event)
P = 0.80
≥ 1 serious adverse reactions
- Similar in the two groups
Original publication
Magnesium sulphate in patients with thrombotic thrombocytopenic purpura (MAGMAT): a randomised, double-blind, superiority trial. Intensive Care Med. Published 23 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →